Angiex Inc. Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Angiex Inc. is a privately held biotechnology startup focused on advancing cancer therapies by exploiting intracellular transport mechanisms to deliver therapeutic payloads to the nucleus or cytosol of tumor cells. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) designed to release their payloads at the site where they exert their effects. Founded by a team of experts in angiogenesis, vascular biology, and oncology, Angiex is based in Cambridge, Massachusetts. With a compact, research-oriented team, the company operates in the biotechnology sector and aims to improve treatment options for solid tumors. A notable recent development is Angiex presenting preclinical in vivo data on AGX101, a TM4SF1-directed ND-ADC, in combination with immune checkpoint inhibitors at the 2026 AACR Annual Meeting.